1-2 of 2
Johan Lanng Nielsen, MD
Close
Sort by
Journal Articles

A Randomized Phase II Study Comparing Imatinib and the Combination of Imatinib and Pegylated Interferon Alpha-2b in Newly Diagnosed Non-High Risk Chronic Myeloid Leukemia (CML) Patients in Complete Hematological Remission After Imatinib Induction Therapy.

Bengt Simonsson, MD, Tobias Gedde-Dahl, MD, Berit Markevärn, MD, Kari Remes, MD, Jesper Stentoft, MD, Anders Almqvist, MD, Mats Björeman, MD, Max Flogegård, MD, Heikki Hallman, MD, Perttu Koskenvesa, MD, Anders Lindblom, MD, Claes Malm, MD, Satu Mustjoki, MD, Kristina Myhr-Eriksson, MD, Anu Räsänen, MD, Marjatta Sinisalo, MD, Risto Sippola, MD, Anders Själander, MD, Ulla Strömberg, MD, Ole Weiss Bjerrum, MD, Hans Ehrencrona, MD, Franz Gruber, MD, Veli Kairisto, MD, Karin RN Olsson, Arnon Nagler, MD, Johan Lanng Nielsen, MD, Henrik Hjorth-Hansen, MD, Kimmo Porkka, MD, for the Nordic CML Study Group (NCMLSG)
Journal: Blood
Blood (2009) 114 (22): 3280.
https://doi.org/10.1182/blood.V114.22.3280.3280
Published: 2009
Journal Articles

Intensive Therapy in Multiple Myeloma. Long-Term Follow-Up with Focus on Relapse after Transplantation. The Nordic Myeloma Study Group (NMSG).

Stig Lenhoff, MD, Martin Hjorth, MD, Johan Lanng Nielsen, MD, Ingemar Turesson, MD, Finn Wislöff, MD, Jan Westin, MD
Journal: Blood
Blood (2004) 104 (11): 938.
https://doi.org/10.1182/blood.V104.11.938.938
Published: 2004